AstraZeneca donates Brixham Environmental Laboratory to Plymouth University
9 December 2013 | By AstraZeneca
The donation of the facility and its equipment will ensure that the laboratory continues to serve scientific and research purposes...
List view / Grid view
News
Gilead announces pivotal phase 2 data for idelalisib in refractory indolent non-hodgkin’s lymphoma
8 December 2013 | By Gilead Sciences
In this study, single-agent treatment with idelalisib achieved an overall response rate of 57 percent with a median duration of response of 12.5 months...
Novartis investigational compound LBH589 significantly extended time without disease progression in Phase III multiple myeloma study
6 December 2013 | By Novartis
LBH589 has potential to be the first in its class of anticancer agents available to patients with multiple myeloma...
European Commission approves Fluenz Tetra for the prevention of seasonal influenza in children
6 December 2013 | By AstraZeneca
Fluenz Tetra is a nasally administered four-strain live attenuated influenza vaccine for the prevention of influenza in children and adolescents from 24 months up to 18 years of age...
GSK launches global consortium with six renowned cancer research centres
5 December 2013 | By GlaxoSmithKline
GlaxoSmithKline plc announced the formation of the Oncology Clinical and Translational Consortium...
Nova Laboratories announces FDA filing of New Drug Application for the treatment of childhood acute lymphoblastic leukemia
4 December 2013 | By Nova Laboratories
The product has been granted orphan drug designation by the FDA, a status given to a product intended for the treatment of a rare disease or condition...
Teva and Takeda announce agreement for glatiramer acetate for multiple sclerosis treatment in Japan
4 December 2013 | By Teva Pharmaceutical Industries
Glatiramer acetate for injection is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis...
Novartis to highlight long-term data, innovative pipeline for patients with hematologic diseases and breast cancer at ASH and SABCS
4 December 2013 | By Novartis
"Cancer treatment has been revolutionized by targeted therapies, which have established a highly successful approach to the management of many cancers..."
AstraZeneca awarded damages in Prilosec® patent litigation
4 December 2013 | By AstraZeneca
AstraZeneca announced a ruling by the US District Court for the Southern District of New York which ordered Apotex Corp., Apotex, Inc and Torpharm, Inc...
New data at American Society of Hematology (ASH) Annuaul Meeting will offer important insights into safe and efficacious use of XARELTO®
3 December 2013 | By
XARELTO® is the most prescribed novel oral anticoagulant in the U.S. Market today...
Sareum Enters Co-Development Agreement in China for Aurora+FLT3 Programme
3 December 2013 | By Sareum Holdings plc
Sareum Holdings plc is pleased to announce that it has signed a co-development agreement with Hebei Medical University Biomedical Engineering Center to advance its Aurora+FLT3 cancer programme...
Lundbeck appoints Senior Vice President for Business Development and HR
3 December 2013 | By Lundbeck
Jacob Tolstrup, Lundbeck's Vice President for Business Development, will now also be in charge of the company's HR department. The Vice President for HR, Teddy Hebo Larsen, has resigned at his own request...
Sanofi announces new phase 3 results for investigational new insulin U300
3 December 2013 | By Sanofi
EDITION II trial demonstrates similar blood sugar control with fewer night-time low blood sugar events for U300 compared with Lantus®...
Ryzodeg® offers improved glycaemic control with significantly lower rates of hypoglycaemia compared to biphasic insulin aspart 30 in adults with type 2 diabetes
3 December 2013 | By Novo Nordisk
Data presented at the World Diabetes Congress of the International Diabetes Federation show that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia...
IDegLira demonstrates superior glycaemic control and weight loss with a low rate of hypoglycaemia for patients uncontrolled on basal insulin
3 December 2013 | By Novo Nordisk
New phase 3 data from the investigational therapy IDegLira were presented at the World Diabetes Congress of the International Diabetes Federation...
